Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study
Publication date: June 2026 Source: Clinical Colorectal Cancer, Volume 25, Issue 2 Author(s): Emerson Y. Chen, Nima Nabavizadeh, Nicholas D. Kendsersky, Christopher Lessenich, Daniel O. Herzig, Elena Korngold, Shaun M. Goodyear, Hagen F. Kennecke, Adel Kardosh, Vassiliki Liana Tsikitis, Kim C. Lu, Sandy Fang, Melissa Wong, Guillaume Joe Pegna, Flavio G. Rocha, Skye C. Mayo, Brian Brinkerhoff, Erin Taber, Brindha Rajagopalan, Byung S. Park
Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000083?dgcid=rss_sd_all
Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000083?dgcid=rss_sd_all
“Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.” Clinical Colorectal Cancer.
@article{article40736,
title = {Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000083?dgcid=rss_sd_all}
}